GlassScriptPhysician profile
Sadaf Q Anwar
NPI 1679560106
$4,562.92
in general payments reported to CMS, 2019-2025
31 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $205 · 2021: $57.79 · 2022: $617 · 2023: $1,278 · 2024: $851 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $867.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $570.90 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $489.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $465.78 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $428.47 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $295.40 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $237.34 | 2022-2025 | |
| Glaxosmithkline, LLC. | $206.65 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $143.53 | 2019-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $140.19 | 2022-2024 | Livalo, Seglentis, Zoryve |
| Janssen Pharmaceuticals, INC | $90.90 | 2019-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $70.25 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $68.97 | 2020-2023 | |
| Idorsia Pharmaceuticals US INC | $49.31 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.03 | 2022-2023 | Xifaxan, Trulance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.15 | 2024-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $38.34 | 2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.93 | 2023 | Synjardy, Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $33.24 | 2022 | |
| Phathom Pharmaceuticals, INC. | $33.19 | 2024 | Voquezna |
| Exact Sciences Corporation | $30.51 | 2024 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $27.95 | 2022 | |
| Merck Sharp & Dohme LLC | $26.50 | 2019-2020 | |
| Vivus LLC | $23.40 | 2023 | Pancreaze |
| Seqirus USA INC | $19.42 | 2022 | |
| Genentech USA, INC. | $17.64 | 2019 | |
| Optinose US, INC. | $16.66 | 2019 | |
| Eisai INC. | $16.62 | 2020 | |
| Allergan, INC. | $13.21 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadaf Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.